NR 565 Advanced Pharmacology Midterm
Exam 2026/2027 | Chamberlain University
Study Guide, Practice Questions, Correct
Answers & Detailed Rationales
NR 565 ADVANCED PHARMACOLOGY MIDTERM EXAM 2026/2027
Chamberlain University Study Guide
OVERVIEW
• This comprehensive study guide contains 200 practice questions designed to
prepare you for the NR 565 Advanced Pharmacology Midterm Exam, covering all
major pharmacological systems and clinical applications.
• Use this material to identify knowledge gaps, reinforce key concepts, and practice
applying pharmacological principles in clinical scenarios through detailed rationales
for each correct answer.
PHARMACOKINETICS & PHARMACODYNAMICS
1. A patient is prescribed a medication with a half-life of 6 hours. After 24
hours of continuous dosing, what percentage of the drug remains in the body
from the first dose?
A) 6.25%
B) 12.5%
C) 25%
D) 50%
E) 75%
CORRECT ANSWER: A) 6.25%
RATIONALE: With a 6-hour half-life, after 24 hours (4 half-lives), the remaining drug
is calculated as (1/2)^4 = 1/16 = 6.25%. Understanding half-life is fundamental to
,determining dosing intervals and steady-state concentrations in advanced
pharmacology.
2. Which of the following processes is responsible for the first-pass
metabolism of orally administered drugs?
A) Hepatic metabolism only
B) Renal excretion
C) Biliary excretion
D) Hepatic and intestinal metabolism
E) Pulmonary elimination
CORRECT ANSWER: D) Hepatic and intestinal metabolism
RATIONALE: Oral drugs undergo first-pass metabolism through both hepatic and
intestinal wall metabolism before reaching systemic circulation. This is why some
drugs have low oral bioavailability and require alternative routes of administration.
3. A patient with liver disease receives a medication with high hepatic
metabolism. What is the most likely pharmacokinetic consequence?
A) Increased clearance
B) Decreased half-life
C) Increased half-life and elevated plasma concentrations
D) Decreased plasma concentrations
E) No change in drug metabolism
CORRECT ANSWER: C) Increased half-life and elevated plasma concentrations
RATIONALE: Hepatic disease reduces the liver's capacity for drug metabolism,
leading to decreased clearance, prolonged half-life, and accumulation of the drug in
plasma. This requires dosage adjustment to prevent toxicity.
,4. What is the primary mechanism by which active transport differs from
passive diffusion in drug absorption?
A) Active transport requires energy and works against concentration gradients
B) Passive diffusion requires carrier proteins
C) Active transport does not require carrier proteins
D) Both processes work equally well regardless of drug concentration
E) Active transport only occurs in the stomach
CORRECT ANSWER: A) Active transport requires energy and works against
concentration gradients
RATIONALE: Active transport is an energy-dependent process mediated by carrier
proteins that can move drugs against concentration gradients, while passive
diffusion relies on concentration gradients and does not require ATP. This
distinction is crucial for understanding drug bioavailability.
5. A 75-year-old patient has reduced renal function with a creatinine
clearance of 30 mL/min. What adjustment is necessary for renally-excreted
medications?
A) No adjustment needed
B) Increase dose frequency
C) Decrease dose and/or increase dosing interval
D) Administer only intravenously
E) Discontinue the medication entirely
CORRECT ANSWER: C) Decrease dose and/or increase dosing interval
RATIONALE: Reduced renal function decreases drug clearance, necessitating dose
reduction or lengthened intervals between doses to prevent drug accumulation and
, toxicity. This is particularly important for elderly patients with declining renal
function.
CARDIOVASCULAR PHARMACOLOGY
6. What is the primary mechanism of action of ACE inhibitors in heart failure
management?
A) Direct vasodilation
B) Beta-adrenergic blockade
C) Inhibition of angiotensin II formation
D) Aldosterone antagonism
E) Direct myocardial stimulation
CORRECT ANSWER: C) Inhibition of angiotensin II formation
RATIONALE: ACE inhibitors block the conversion of angiotensin I to angiotensin II,
reducing vasoconstriction and aldosterone release. This decreases preload and
afterload, improving cardiac output in heart failure patients and preventing
ventricular remodeling.
7. A patient on lisinopril develops a persistent dry cough. What is the
pharmacological basis for this adverse effect?
A) Direct irritation of the airways
B) Accumulation of bradykinin due to ACE inhibition
C) Pulmonary edema
D) Allergic reaction to the drug
E) Increased angiotensin II levels
CORRECT ANSWER: B) Accumulation of bradykinin due to ACE inhibition
Exam 2026/2027 | Chamberlain University
Study Guide, Practice Questions, Correct
Answers & Detailed Rationales
NR 565 ADVANCED PHARMACOLOGY MIDTERM EXAM 2026/2027
Chamberlain University Study Guide
OVERVIEW
• This comprehensive study guide contains 200 practice questions designed to
prepare you for the NR 565 Advanced Pharmacology Midterm Exam, covering all
major pharmacological systems and clinical applications.
• Use this material to identify knowledge gaps, reinforce key concepts, and practice
applying pharmacological principles in clinical scenarios through detailed rationales
for each correct answer.
PHARMACOKINETICS & PHARMACODYNAMICS
1. A patient is prescribed a medication with a half-life of 6 hours. After 24
hours of continuous dosing, what percentage of the drug remains in the body
from the first dose?
A) 6.25%
B) 12.5%
C) 25%
D) 50%
E) 75%
CORRECT ANSWER: A) 6.25%
RATIONALE: With a 6-hour half-life, after 24 hours (4 half-lives), the remaining drug
is calculated as (1/2)^4 = 1/16 = 6.25%. Understanding half-life is fundamental to
,determining dosing intervals and steady-state concentrations in advanced
pharmacology.
2. Which of the following processes is responsible for the first-pass
metabolism of orally administered drugs?
A) Hepatic metabolism only
B) Renal excretion
C) Biliary excretion
D) Hepatic and intestinal metabolism
E) Pulmonary elimination
CORRECT ANSWER: D) Hepatic and intestinal metabolism
RATIONALE: Oral drugs undergo first-pass metabolism through both hepatic and
intestinal wall metabolism before reaching systemic circulation. This is why some
drugs have low oral bioavailability and require alternative routes of administration.
3. A patient with liver disease receives a medication with high hepatic
metabolism. What is the most likely pharmacokinetic consequence?
A) Increased clearance
B) Decreased half-life
C) Increased half-life and elevated plasma concentrations
D) Decreased plasma concentrations
E) No change in drug metabolism
CORRECT ANSWER: C) Increased half-life and elevated plasma concentrations
RATIONALE: Hepatic disease reduces the liver's capacity for drug metabolism,
leading to decreased clearance, prolonged half-life, and accumulation of the drug in
plasma. This requires dosage adjustment to prevent toxicity.
,4. What is the primary mechanism by which active transport differs from
passive diffusion in drug absorption?
A) Active transport requires energy and works against concentration gradients
B) Passive diffusion requires carrier proteins
C) Active transport does not require carrier proteins
D) Both processes work equally well regardless of drug concentration
E) Active transport only occurs in the stomach
CORRECT ANSWER: A) Active transport requires energy and works against
concentration gradients
RATIONALE: Active transport is an energy-dependent process mediated by carrier
proteins that can move drugs against concentration gradients, while passive
diffusion relies on concentration gradients and does not require ATP. This
distinction is crucial for understanding drug bioavailability.
5. A 75-year-old patient has reduced renal function with a creatinine
clearance of 30 mL/min. What adjustment is necessary for renally-excreted
medications?
A) No adjustment needed
B) Increase dose frequency
C) Decrease dose and/or increase dosing interval
D) Administer only intravenously
E) Discontinue the medication entirely
CORRECT ANSWER: C) Decrease dose and/or increase dosing interval
RATIONALE: Reduced renal function decreases drug clearance, necessitating dose
reduction or lengthened intervals between doses to prevent drug accumulation and
, toxicity. This is particularly important for elderly patients with declining renal
function.
CARDIOVASCULAR PHARMACOLOGY
6. What is the primary mechanism of action of ACE inhibitors in heart failure
management?
A) Direct vasodilation
B) Beta-adrenergic blockade
C) Inhibition of angiotensin II formation
D) Aldosterone antagonism
E) Direct myocardial stimulation
CORRECT ANSWER: C) Inhibition of angiotensin II formation
RATIONALE: ACE inhibitors block the conversion of angiotensin I to angiotensin II,
reducing vasoconstriction and aldosterone release. This decreases preload and
afterload, improving cardiac output in heart failure patients and preventing
ventricular remodeling.
7. A patient on lisinopril develops a persistent dry cough. What is the
pharmacological basis for this adverse effect?
A) Direct irritation of the airways
B) Accumulation of bradykinin due to ACE inhibition
C) Pulmonary edema
D) Allergic reaction to the drug
E) Increased angiotensin II levels
CORRECT ANSWER: B) Accumulation of bradykinin due to ACE inhibition
